BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Berg DR, Colombel JF, Ungaro R. The Role of Early Biologic Therapy in Inflammatory Bowel Disease. Inflamm Bowel Dis 2019;25:1896-905. [PMID: 30934053 DOI: 10.1093/ibd/izz059] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 15.5] [Reference Citation Analysis]
Number Citing Articles
1 Papaefthymiou A, Potamianos S, Goulas A, Doulberis M, Kountouras J, Polyzos SA. Inflammatory Bowel Disease-associated Fatty Liver Disease: the Potential Effect of Biologic Agents. J Crohns Colitis 2021:jjab212. [PMID: 34972203 DOI: 10.1093/ecco-jcc/jjab212] [Reference Citation Analysis]
2 Barnes EL, Jiang Y, Kappelman MD, Long MD, Sandler RS, Kinlaw AC, Herfarth HH. Decreasing Colectomy Rate for Ulcerative Colitis in the United States Between 2007 and 2016: A Time Trend Analysis. Inflamm Bowel Dis 2020;26:1225-31. [PMID: 31634390 DOI: 10.1093/ibd/izz247] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
3 Park SH, Park SH. Personalized medicine in inflammatory bowel disease: Perspectives on Asia. J Gastroenterol Hepatol 2022. [PMID: 35726657 DOI: 10.1111/jgh.15919] [Reference Citation Analysis]
4 Hamdeh S, Aziz M, Altayar O, Olyaee M, Murad MH, Hanauer SB. Early vs Late Use of Anti-TNFa Therapy in Adult Patients With Crohn Disease: A Systematic Review and Meta-Analysis. Inflamm Bowel Dis 2020;26:1808-18. [PMID: 32064534 DOI: 10.1093/ibd/izaa031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Fathallah N, Cristea C, Beaussier H, Khirani S, de Parades V. Infliximab for Anoperineal Lesions in Crohn's Disease: Remission Appears to be Based on Rapid Combination Therapy at High Doses. Journal of Coloproctology. [DOI: 10.1055/s-0041-1739549] [Reference Citation Analysis]
6 Naftali T, Richter V, Mari A, Khoury T, Shirin H, Broide E. The inflammatory bowel disease disk application: A platform to assess patients' priorities and expectations from treatment. J Dig Dis 2021;22:582-9. [PMID: 34431218 DOI: 10.1111/1751-2980.13045] [Reference Citation Analysis]
7 Marsal J, Barreiro-de Acosta M, Blumenstein I, Cappello M, Bazin T, Sebastian S. Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. Front Med 2022;9:897936. [DOI: 10.3389/fmed.2022.897936] [Reference Citation Analysis]
8 Parrish RH. Biosimilar Interchangeability and Emerging Treatment Strategies for Inflammatory Bowel Diseases: A Commentary. Gastroenterology Insights 2021;12:293-301. [DOI: 10.3390/gastroent12030026] [Reference Citation Analysis]
9 Lashgari NA, Momeni Roudsari N, Khayatan D, Shayan M, Momtaz S, Roufogalis BD, Abdolghaffari AH, Sahebkar A. Ginger and its constituents: Role in treatment of inflammatory bowel disease. Biofactors 2021. [PMID: 34882874 DOI: 10.1002/biof.1808] [Reference Citation Analysis]
10 Ministro P, Dias CC, Portela F, Fernandes S, Bernardo S, Pires F, Lago P, Rosa I, Trindade E, Alves C, Correia L, Magro F. Age at Diagnosis Is Determinant for the Outcome of Inflammatory Bowel Disease: Is It a Myth? Clin Transl Gastroenterol 2021;12:e00309. [PMID: 33587489 DOI: 10.14309/ctg.0000000000000309] [Reference Citation Analysis]
11 Kim SY, An S, Park DK, Kwon KA, Kim KO, Chung JW, Kim JH, Kim YJ. Efficacy of iron supplementation in patients with inflammatory bowel disease treated with anti-tumor necrosis factor-alpha agents. Therap Adv Gastroenterol 2020;13:1756284820961302. [PMID: 33029199 DOI: 10.1177/1756284820961302] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 D'Amico F, Tasopoulou O, Fiorino G, Zilli A, Furfaro F, Allocca M, Sileri P, Spinelli A, Peyrin-Biroulet L, Danese S. Early Biological Therapy in Operated Crohn's Disease Patients Is Associated With a Lower Rate of Endoscopic Recurrence and Improved Long-term Outcomes: A Single-center Experience. Inflamm Bowel Dis 2022:izac110. [PMID: 35640113 DOI: 10.1093/ibd/izac110] [Reference Citation Analysis]
13 Tapete G, Bertani L, Pieraccini A, Lynch EN, Giannotta M, Morganti R, Biviano I, Naldini S, Mumolo MG, De Nigris F, Calella F, Bagnoli S, Minciotti M, Maltinti S, Rentini S, Ceccarelli L, Lionetti P, Milla M, Costa F. Effectiveness and Safety of Nonmedical Switch From Adalimumab Originator to SB5 Biosimilar in Patients With Inflammatory Bowel Diseases: Twelve-Month Follow-Up From the TABLET Registry. Inflamm Bowel Dis 2021:izab027. [PMID: 33570142 DOI: 10.1093/ibd/izab027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
14 Chang S, Hudesman D. First-Line Biologics or Small Molecules in Inflammatory Bowel Disease: a Practical Guide for the Clinician. Curr Gastroenterol Rep 2020;22:7. [PMID: 32002688 DOI: 10.1007/s11894-020-0745-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
15 Yi YS. Dual roles of the caspase-11 non-canonical inflammasome in inflammatory bowel disease. Int Immunopharmacol 2022;108:108739. [PMID: 35366642 DOI: 10.1016/j.intimp.2022.108739] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Laharie D, D'Haens G, Nachury M, Lambrecht G, Bossuyt P, Bouhnik Y, Louis E, Janneke van der Woude C, Buisson A, Van Hootegem P, Allez M, Filippi J, Brixi H, Gilletta C, Picon L, Baert F, Vermeire S, Duveau N, Peyrin-Biroulet L. Steroid-Free Deep Remission at One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01268-4. [PMID: 34843987 DOI: 10.1016/j.cgh.2021.11.030] [Reference Citation Analysis]
17 Laurain P, Guillo L, D’amico F, Netter P, Danese S, Baumann C, Luc A, Clerc-urmes I, Sofos S, Peyrin-biroulet L. Incidence of and Risk Factors for Colorectal Strictures in Ulcerative Colitis: A Multicenter Study. Clinical Gastroenterology and Hepatology 2021;19:1899-1905.e1. [DOI: 10.1016/j.cgh.2021.01.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Antunes JC, Seabra CL, Domingues JM, Teixeira MO, Nunes C, Costa-Lima SA, Homem NC, Reis S, Amorim MTP, Felgueiras HP. Drug Targeting of Inflammatory Bowel Diseases by Biomolecules. Nanomaterials (Basel) 2021;11:2035. [PMID: 34443866 DOI: 10.3390/nano11082035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
19 Solitano V, D'Amico F, Fiorino G, Paridaens K, Peyrin-Biroulet L, Danese S. Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis. J Clin Med 2020;9:E2905. [PMID: 32911840 DOI: 10.3390/jcm9092905] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Everhov ÅH, Sachs MC, Ludvigsson JF, Khalili H, Askling J, Neovius M, Myrelid P, Halfvarson J, Nordenvall C, Söderling J, Olén O; SWIBREG study group. Work Loss in Relation to Pharmacological and Surgical Treatment for Crohn's Disease: A Population-Based Cohort Study. Clin Epidemiol 2020;12:273-85. [PMID: 32210631 DOI: 10.2147/CLEP.S244011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
21 Scarallo L, Alvisi P, Bolasco G, Di Toma M, Lanari M, Cangiari A, Paci M, Naldini S, Renzo S, Barp J, De Masi S, Lionetti P. Mucosal and Histologic Healing in Children With Inflammatory Bowel Disease Treated With Antitumor Necrosis Factor-Alpha. J Pediatr Gastroenterol Nutr 2021;72:728-35. [PMID: 33399329 DOI: 10.1097/MPG.0000000000003043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Solitano V, D'Amico F, Zacharopoulou E, Peyrin-Biroulet L, Danese S. Early Intervention in Ulcerative Colitis: Ready for Prime Time? J Clin Med 2020;9:E2646. [PMID: 32823997 DOI: 10.3390/jcm9082646] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
23 Ferretti F, Cannatelli R, Monico MC, Maconi G, Ardizzone S. An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis. J Clin Med 2022;11:2302. [PMID: 35566428 DOI: 10.3390/jcm11092302] [Reference Citation Analysis]
24 Rubin DT, Griffith J, Zhang Q, Hepp Z, Keshishian A. The Impact of Intestinal Complications on Health Care Costs Among Patients With Inflammatory Bowel Disease Treated With Anti-Tumor Necrosis Factor Therapies. Inflamm Bowel Dis 2021;27:1201-9. [PMID: 33107564 DOI: 10.1093/ibd/izaa270] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Avery P. Developments and challenges of e-health strategies for people with inflammatory bowel disease. British Journal of Healthcare Management 2020;26:73-6. [DOI: 10.12968/bjhc.2020.0010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Privitera G, Pugliese D, Lopetuso LR, Scaldaferri F, Neri M, Guidi L, Gasbarrini A, Armuzzi A. Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches. Therap Adv Gastroenterol 2021;14:17562848211006669. [PMID: 33995579 DOI: 10.1177/17562848211006669] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
27 Fossmark R, Olaisen M, Martinsen TC, Melberg HO. Factors associated with the persistence of oral 5-aminosalicylic acid monotherapy in ulcerative colitis: a nationwide Norwegian cohort study. Therap Adv Gastroenterol 2021;14:17562848211021760. [PMID: 34262610 DOI: 10.1177/17562848211021760] [Reference Citation Analysis]
28 Ungaro RC, Yzet C, Bossuyt P, Baert FJ, Vanasek T, D'Haens GR, Joustra VW, Panaccione R, Novacek G, Reinisch W, Armuzzi A, Golovchenko O, Prymak O, Goldis A, Travis SP, Hébuterne X, Ferrante M, Rogler G, Fumery M, Danese S, Rydzewska G, Pariente B, Hertervig E, Stanciu C, Serrero M, Diculescu M, Peyrin-Biroulet L, Laharie D, Wright JP, Gomollón F, Gubonina I, Schreiber S, Motoya S, Hellström PM, Halfvarson J, Butler JW, Petersson J, Petralia F, Colombel JF. Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease. Gastroenterology 2020;159:139-47. [PMID: 32224129 DOI: 10.1053/j.gastro.2020.03.039] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 14.5] [Reference Citation Analysis]
29 Romeo S, Neri B, Mossa M, Calabrese E, Lolli E, Sena G, Gesuale C, Chiaramonte C, Biancone L. Finger clubbing in inflammatory bowel disease: association with upper small bowel lesions and need of surgery in Crohn's disease. Eur J Gastroenterol Hepatol 2021;33:844-51. [PMID: 33136723 DOI: 10.1097/MEG.0000000000001966] [Reference Citation Analysis]
30 Pękala A, Filip R. Levels of Biosimilar Infliximab during and after Induction Treatment in Crohn's Disease and Ulcerative Colitis-A Prospective Polish Population Study. J Clin Med 2021;10:5311. [PMID: 34830598 DOI: 10.3390/jcm10225311] [Reference Citation Analysis]
31 Manthey CF, Reher D, Huber S. [What is confirmed in the treatment of chronic inflammatory bowel diseases]. Internist (Berl) 2021. [PMID: 34727190 DOI: 10.1007/s00108-021-01207-6] [Reference Citation Analysis]
32 Carvello M, Danese S, Spinelli A. Surgery versus Medical Therapy in Luminal Ileocecal Crohn's Disease. Clin Colon Rectal Surg 2022;35:072-7. [DOI: 10.1055/s-0041-1740031] [Reference Citation Analysis]
33 Kelm M, Germer CT, Schlegel N, Flemming S. The Revival of Surgery in Crohn's Disease-Early Intestinal Resection as a Reasonable Alternative in Localized Ileitis. Biomedicines 2021;9:1317. [PMID: 34680434 DOI: 10.3390/biomedicines9101317] [Reference Citation Analysis]
34 Ungaro RC, Aggarwal S, Topaloglu O, Lee WJ, Clark R, Colombel JF. Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn's disease. Aliment Pharmacol Ther 2020;51:831-42. [PMID: 32202328 DOI: 10.1111/apt.15685] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
35 Rodríguez-Lago I, Zabana Y, Barreiro-de Acosta M. Diagnosis and natural history of preclinical and early inflammatory bowel disease. Ann Gastroenterol 2020;33:443-52. [PMID: 32879589 DOI: 10.20524/aog.2020.0508] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Pillai N, Lupatsch JE, Dusheiko M, Schwenkglenks M, Maillard M, Sutherland CS, Pittet VEH, Anderegg C, Bauerfeind P, Beglinger C, Begré S, Belli D, Bengoa JM, Biedermann L, Bigler B, Binek J, Blattmann M, Boehm S, Borovicka J, Braegger CP, Brunner N, Bühr P, Burnand B, Burri E, Buyse S, Cremer M, Criblez DH, de Saussure P, Degen L, Delarive J, Doerig C, Dora B, Dorta G, Egger M, Ehmann T, El-wafa A, Engelmann M, Ezri J, Felley C, Fliegner M, Fournier N, Fraga M, Frei P, Frei R, Fried M, Froehlich F, Funk C, Furlano RI, Gallot-lavallée S, Geyer M, Girardin M, Golay D, Grandinetti T, Gysi B, Haack H, Haarer J, Helbling B, Hengstler P, Herzog D, Hess C, Heyland K, Hinterleitner T, Hiroz P, Hirschi C, Hruz P, Iwata R, Jost R, Juillerat P, Keller C, Knellwolf C, Knoblauch C, Köhler H, Koller R, Krieger-grübel C, Kullak-ublick G, Künzler P, Landolt M, Lange R, Lehmann FS, Macpherson A, Maerten P, Maillard MH, Manser C, Manz M, Marbet U, Marx G, Matter C, Meier R, Mendanova M, Michetti P, Misselwitz B, Morell B, Mosler P, Mottet C, Müller C, Müller P, Müllhaupt B, Münger-beyeler C, Musso L, Nagy A, Neagu M, Nichita C, Niess J, Nydegger A, Obialo N, Oneta C, Oropesa C, Peter U, Peternac D, Petit LM, Piccoli-gfeller F, Pilz JB, Pittet V, Raschle N, Rentsch R, Restellini S, Richterich J, Rihs S, Ritz MA, Roduit J, Rogler D, Rogler G, Rossel J, Rueger V, Saner G, Sauter B, Sawatzki M, Schäppi M, Scharl M, Scharl S, Schelling M, Schibli S, Schlauri H, Uebelhart SS, Schnegg J, Schoepfer A, Seibold F, Seirafi M, Semadeni G, Semela D, Senning A, Sidler M, Sokollik C, Spalinger J, Spangenberger H, Stadler P, Steuerwald M, Straumann A, Straumann-funk B, Sulz M, Suter A, Thorens J, Tiedemann S, Tutuian R, Vavricka S, Viani F, Vögtlin J, Von Känel R, Vonlaufen A, Vouillamoz D, Vulliamy R, Wermuth J, Werner H, Wiesel P, Wiest R, Wylie T, Zeitz J, Zimmermann D; Swiss IBD Cohort Study group. Evaluating the Cost-Effectiveness of Early Compared with Late or No Biologic Treatment to Manage Crohn’s Disease using Real-World Data. Journal of Crohn's and Colitis 2020;14:490-500. [DOI: 10.1093/ecco-jcc/jjz169] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
37 Al Sulais E, AlAmeel T. Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease. Biologics 2020;14:1-11. [PMID: 32021084 DOI: 10.2147/BTT.S236433] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 Ma S, Zhang J, Liu H, Li S, Wang Q. The Role of Tissue-Resident Macrophages in the Development and Treatment of Inflammatory Bowel Disease. Front Cell Dev Biol 2022;10:896591. [PMID: 35721513 DOI: 10.3389/fcell.2022.896591] [Reference Citation Analysis]
39 Kapoor A, Crowley E. Advances in Therapeutic Drug Monitoring in Biologic Therapies for Pediatric Inflammatory Bowel Disease. Front Pediatr 2021;9:661536. [PMID: 34123968 DOI: 10.3389/fped.2021.661536] [Reference Citation Analysis]
40 Bastida G, Marín-Jiménez I, Forés A, García-Planella E, Argüelles-Arias F, Tagarro I, Fernandez-Nistal A, Montoto C, Aparicio J, Aguas M, Santos-Fernández J, Boscá-Watts MM, Ferreiro-Iglesias R, Merino O, Aldeguer X, Cortés X, Sicilia B, Mesonero F, Barreiro-de Acosta M. Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFα used for the treatment of IBD: Results from the VERNE study. Dig Liver Dis 2021:S1590-8658(21)00319-4. [PMID: 34244110 DOI: 10.1016/j.dld.2021.06.005] [Reference Citation Analysis]
41 Syversen SW, Jørgensen KK, Goll GL, Brun MK, Sandanger Ø, Bjørlykke KH, Sexton J, Olsen IC, Gehin JE, Warren DJ, Klaasen RA, Noraberg G, Bruun TJ, Dotterud CK, Ljoså MKA, Haugen AJ, Njålla RJ, Zettel C, Ystrøm CM, Bragnes YH, Skorpe S, Thune T, Seeberg KA, Michelsen B, Blomgren IM, Strand EK, Mielnik P, Torp R, Mørk C, Kvien TK, Jahnsen J, Bolstad N, Haavardsholm EA. Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial. JAMA 2021;326:2375-84. [PMID: 34932077 DOI: 10.1001/jama.2021.21316] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
42 Caviglia GP, Rosso C, Stalla F, Rizzo M, Massano A, Abate ML, Olivero A, Armandi A, Vanni E, Younes R, Fagoonee S, Pellicano R, Astegiano M, Saracco GM, Bugianesi E, Ribaldone DG. On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases. J Clin Med 2020;9:E800. [PMID: 32183476 DOI: 10.3390/jcm9030800] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
43 Haider M, Lashner B. Dual Targeted Therapy for the Management of Inflammatory Bowel Disease. J Clin Gastroenterol 2021;55:661-6. [PMID: 34238847 DOI: 10.1097/MCG.0000000000001583] [Reference Citation Analysis]
44 Blackwell J, Saxena S, Jayasooriya N, Bottle A, Petersen I, Hotopf M, Alexakis C, Pollok RC. Prevalence and Duration of Gastrointestinal Symptoms Before Diagnosis of Inflammatory Bowel Disease and Predictors of Timely Specialist Review: A Population-Based Study. Journal of Crohn's and Colitis 2021;15:203-11. [DOI: 10.1093/ecco-jcc/jjaa146] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
45 Sulkanen E, Repo M, Huhtala H, Hiltunen P, Kurppa K. Impact of diagnostic delay to the clinical presentation and associated factors in pediatric inflammatory bowel disease: a retrospective study. BMC Gastroenterol 2021;21:364. [PMID: 34620103 DOI: 10.1186/s12876-021-01938-8] [Reference Citation Analysis]